OBJECTIVE: This article reports a case of medication-related osteonecrosis of the jaw (MRONJ) associated with multiple myeloma (MM). BACKGROUND: Bisphosphonates (BPs) are constantly used as part of the treatment for MM. The main adverse effects of bisphosphonates are renal insufficiency and medication-related osteonecrosis of the jaw (MRONJ). MATERIALS AND METHODS: A 67-year-old female with a previous diagnosis of MM and undergoing current receiving intravenous injections of pamidronate underwent a tooth extraction and subsequently developed MRONJ. RESULTS: MRONJ was managed with clindamycin, surgical removal of bony sequestrum and curettage. At 3 years of follow-up, the patient was asymptomatic with no clinical changes and panoramic radiography without evidence of recurrence. CONCLUSION: Management of patients under antiresorptive drugs who require invasive dental procedures is challenging. Therefore, interprofessional collaboration, especially between the general practitioner and oncologist and/or haematologist, is essential to reach the best clinical approach and reduce the risk of MRONJ.